ROCK1
Rho-associated protein kinase 1
As of the edition of 20 October 2026, ROCK1 (rho-associated protein kinase 1, UniProt Q13464) has 9 drugs tested at it and 9 companies on the list, 1 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13464
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 33
- Disease areas
- Eye; Immune system; Lungs and airways; Inherited and neonatal; Cancer; Nervous system; Heart and blood vessels; Nutrition and metabolism
- Registered trials of its drugs
- 117
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Went quiet | 3 |
| Stopped | 2 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Belumosudil | Marketed | Phase 4 | Ends 2034 |
| Netarsudil | Marketed | Phase 4 | Ends 2034 |
| Fasudil | Stopped | Phase 4 | none listed |
| Ripasudil | Marketed | Phase 3 | none listed |
| Verosudil | Went quiet | Phase 2 | none listed |
| AMA0076 | Active | Phase 3 | none listed |
| Sar-407899 free base | Stopped | Phase 2 | none listed |
| AT-13148 | Went quiet | Phase 1 | none listed |
| DE-104 | Went quiet | Phase 2 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 5 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 9 |
The other 6 companies at ROCK1
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at ROCK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.